(Q54944010)

13 June 2018

title

Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. (English)

1 reference

13 June 2018

1 reference

1 reference

1 reference

1 reference

S Kudoh

1

1 reference

13 June 2018

M Fukuoka

2

1 reference

13 June 2018

N Masuda

3

1 reference

13 June 2018

A Yoshikawa

4

1 reference

13 June 2018

Y Kusunoki

5

1 reference

13 June 2018

K Matsui

6

1 reference

13 June 2018

S Negoro

7

1 reference

13 June 2018

N Takifuji

8

1 reference

13 June 2018

K Nakagawa

9

1 reference

13 June 2018

T Hirashima

10

1 reference

13 June 2018

publication date

1 April 1995

1 reference

13 June 2018

number of pages

8

1 reference

Japanese Journal of Cancer Research

inferred from page(s)

published in

1 reference

13 June 2018

volume

86

1 reference

13 June 2018

issue

4

1 reference

13 June 2018

page(s)

406-413

1 reference

13 June 2018

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

The current status of camptothecin analogues as antitumor agents

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

DNA topoisomerase poisons as antitumor drugs

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920836

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

13 August 2018

1 reference

12 December 2020

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I

1 reference

12 December 2020

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer

1 reference

12 December 2020

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

12 December 2020

Phase I clinical study of CPT-11. Research group of CPT-11

1 reference

12 December 2020

Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse

1 reference

12 December 2020

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

1 reference

12 December 2020

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

12 December 2020

10.1111/J.1349-7006.1995.TB03071.X

Identifiers

DOI

1 reference

13 June 2018

PMC publication ID

5920836

1 reference

13 June 2018

PubMed publication ID

7775263

1 reference

13 June 2018